Fundamental Analysis of Takeda Pharma Co Ltd. - Growth / Value Index
TAK - Valuation Highlights
Valuation Analysis
Tsr Value Index - Good Score of 68.75
Undervalued - Price to Intrinsic Value of 0.0008
Price to Earning Ratio is 0.184 and EV to EBITDA is -0.059 suggesting company is undervalued.
Price to Book Ratio is 0.0038 indicating that it is undervalued.
Tremendous increasing in Book Value last 3 year
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 0.180 | 0.145 | 123.70 % | |
| Price to Book | 0.0038 | 0.0029 | -11.19 % | 0.0029 |
| Price to Sales | 0.0061 | 0.0049 | -3.97 % | |
| Enterprise Value to EBITDA Multiple | -0.060 | -0.062 | -101.93 % |
TAK - Profitability Highlights
Profitability Analysis
Earning Yield of 544.63 %
Reasonable Dividend Yield of 4.82 %
Tsr Profitability Index - Very Poor Score of 5.00
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 2.10 | 1.98 | -60.30 % | -0.0415 |
| Return On Asset | 0.987 | 0.954 | -58.02 % | -0.0200 |
| Net Profit Margin | 3.38 | 3.38 | -57.07 % | -0.287 |
| Operating Profit Margin | 5.27 | 9.41 | -22.74 % | 0.051 |
| EBITDA Margin | 19.24 | 26.48 | -11.79 % | 17.82 |
Highlights
| Market Cap | 41484.76 M |
| Enterprise Value | -49064.24 M |
| Price/Book TTM | 0.0038 |
| Outstanding Share | 3138.03 M |
| Float/ Outstanding Share | 49.40% |
| Dividend Yield | 4.79 % |
Share Holding
Guru Numbers
| Price/Graham No | 0.0048 |
| Peter Lynch Ratio | -306.14 |
| Piotroski F Score | 6.00 |
| Altman Z Score | 0.502 |
| Sloan Ratio | -0.0328 |
| Peter Lynch Fair Value | 1621.00 |
TAK - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Steady increase in Total Assets for last 3 Years
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 4263.76 B | 5.87 % | 5.43 % |
| Gross Profit | 2650.34 B | 21.50 % | 34.18 % |
| EBITDA | 820245 M | 6.61 % | 40.53 % |
| Net Profit | 144066 M | 54.56 % | 102.85 % |
| EPS | 73.25 | 55.30 % | NA |
TAK - Stability Highlights
Stability Analysis
Tsr Stability Index - Good Score of 71.88
Paid More Than 50% of Debt, Heading towards debt free
Debt to equity ratio has decreased and is lowest in last five years
Altman Z Score of 0.502 suggest high risk
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.050 | -92.68 % | 0.050 |
| Cash Ratio | 0.198 | -11.29 % | |
| Quick Ratio | 0.583 | 2.53 % | 0.583 |
| Shareholders Equity | 48.14 | 5.74 % | |
| Debt to EBITDA | 0.325 | -91.03 % |
Historical Valuation Ratios of Takeda Pharma Co Ltd.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Takeda Pharma Co Ltd.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Takeda Pharma Co Ltd.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Takeda Pharma Co Ltd.
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)